The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant cells displayed moderate to strong cytoplasmic immunoreactivity with a granular pattern.
A majority of cancers displayed moderate cytoplasmic immunoreactivity. Several cases of colorectal, liver and prostate cancers exhibited strong positivity. Skin cancers were negative.
Most malignancies were negative. Several malignant melanomas, thyroid, gastric, liver and colorectal cancers showed moderate cytoplasmic staining.
Moderate to strong cytoplasmic positivity with a granular pattern was observed in most malignant tissues. Most liver, colorectal and pancreatic cancers exhibited strong staining. Basal cell carcinomas in skin were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
